QR Pharma, Inc. announced today a new collaborative research agreement with The Rockefeller University aimed at developing a treatment for Huntington's disease . "QR Pharma's technology targets the mRNA of a number of proteins that are over expressed in several neurological disorders, such as Alzheimer's disease, Parkinson's disease, Down Syndrome, and Huntington's disease in a manner that has the potential to impact disease progression" The collaboration will focus on preclinical research involving QR's lead drug candidate, Posiphen .
http://ift.tt/1Ksc4OW
http://ift.tt/1Ksc4OW
No comments:
Post a Comment